NeuBase Therapeutics (NBSE) Short Interest Ratio & Short Volume → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free NBSE Stock Alerts $0.38 -0.01 (-3.20%) (As of 05/10/2024 03:59 PM ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability NeuBase Therapeutics Short Interest DataCurrent Short Volume15,600 sharesPrevious Short Volume24,500 sharesChange Vs. Previous Month-36.33%Dollar Volume Sold Short$6,583.20Short Interest Ratio / Days to Cover0.1Last Record DateApril 30, 2024Outstanding Shares3,750,000 sharesFloat Size3,050,000 sharesShort Percent of Float0.51%Today's Trading Volume97,700 sharesAverage Trading Volume191,869 sharesToday's Volume Vs. Average51% Short Selling NeuBase Therapeutics ? Sign up to receive the latest short interest report for NeuBase Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatNBSE Short Interest Over TimeNBSE Days to Cover Over TimeNBSE Percentage of Float Shorted Over Time Ad InvestorPlaceYour Portfolio’s Shield Against Inflation: Gold’s Surge and AI BreakthroughsWhile gold may be thanking China for its recent growth, this sector is currently thanking Elon Musk. As crazy as it sounds, artificial intelligence just got one step closer to ushering in "the next step in human evolution"... and minting new millionaires. And it's all thanks to Musk's latest AI creation.Click to watch this device in action NeuBase Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202415,600 shares $6,583.20 -36.3%0.5%0.1 $0.42 4/15/202424,500 shares $10,221.40 -83.6%0.8%0.1 $0.42 3/31/2024149,100 shares $67,080.09 +85.2%4.9%0.6 $0.45 3/15/202480,500 shares $78,004.50 -59.7%2.7%0.4 $0.97 2/29/2024199,800 shares $171,828.00 +2,003.2%6.6%1 $0.86 2/15/20249,500 shares $6,508.45 -24.6%0.3%0 $0.69 Get the Latest News and Ratings for NBSE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/202412,600 shares $8,983.80 +14.6%0.4%0 $0.71 1/15/202411,000 shares $7,291.90 -82.6%0.4%0 $0.66 12/31/202363,300 shares $46,848.33 +245.9%2.1%0.2 $0.74 12/15/202318,300 shares $12,810.00 +105.6%0.6%0.1 $0.70 11/30/20238,900 shares $8,778.96 -27.6%0.3%0 $0.99 11/15/202312,300 shares $8,007.30 +38.2%0.5%0 $0.65 10/31/20238,900 shares $5,651.50 -53.9%0.6%0 $0.64 10/15/202319,300 shares $14,457.63 -15.4%1.2%0 $0.75 9/30/202322,800 shares $19,831.44 -89.9%1.4%0 $0.87 9/15/2023225,600 shares $293,280.00 +30.8%14.0%0.1 $1.30 8/31/2023172,500 shares $167,325.00 +130.3%19.3%0.1 $0.97 8/15/202374,900 shares $51,531.20 +82.2%3.8%0.4 $0.69 7/31/202341,100 shares $57,129.00 -61.4%2.4%0.3 $1.39 7/15/2023106,600 shares $187,616.00 +49.1%7.5%1.4 $1.76 6/30/202371,500 shares $132,275.00 +108.5%5.0%1 $1.85 6/15/202334,300 shares $1.89 million -93.8%2.4%0.5 $55.20 5/31/2023554,800 shares $98,809.88 -1.7%2.0%1.2 $0.18 5/15/2023564,400 shares $108,929.20 +0.7%2.0%1.3 $0.19 4/30/2023560,400 shares $75,654.00 +64.4%2.0%1.1 $0.14 4/15/2023340,900 shares $57,271.20 +35.5%1.2%0.7 $0.17 3/31/2023251,600 shares $46,546.00 -8.1%0.9%0.8 $0.19 3/15/2023273,800 shares $51,282.74 -15.1%1.0%0.8 $0.19 2/28/2023322,500 shares $74,175.00 -46.3%1.2%0.9 $0.23 2/15/2023600,100 shares $169,708.28 +127.1%2.2%1.8 $0.28 1/31/2023264,300 shares $60,181.11 -13.2%0.9%1 $0.23 1/15/2023304,400 shares $78,961.36 -24.7%1.0%1.2 $0.26 12/30/2022404,400 shares $76,916.88 +27.1%1.4%1.8 $0.19 12/15/2022318,200 shares $63,130.88 +12.0%1.1%1.7 $0.20 11/30/2022284,200 shares $68,122.74 -5.1%1.0%1.8 $0.24 11/15/2022299,500 shares $86,855.00 -24.1%1.0%1.9 $0.29 10/31/2022394,500 shares $113,221.50 +11.8%1.4%3.2 $0.29 10/15/2022353,000 shares $95,592.40 +10.4%1.2%3.4 $0.27 9/30/2022319,900 shares $126,360.50 -3.6%1.1%4.3 $0.40 9/15/2022331,700 shares $181,771.60 -3.8%1.1%5.1 $0.55Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. NBSE Short Interest - Frequently Asked Questions What is NeuBase Therapeutics' current short interest? Short interest is the volume of NeuBase Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 15,600 shares of NBSE short. 0.51% of NeuBase Therapeutics' shares are currently sold short. Learn More on NeuBase Therapeutics' current short interest. What is a good short interest percentage for NeuBase Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.51% of NeuBase Therapeutics' floating shares are currently sold short. Is NeuBase Therapeutics' short interest increasing or decreasing? NeuBase Therapeutics saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 15,600 shares, a decline of 36.3% from the previous total of 24,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is NeuBase Therapeutics' float size? NeuBase Therapeutics currently has issued a total of 3,750,000 shares. Some of NeuBase Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. NeuBase Therapeutics currently has a public float of 3,050,000 shares. How does NeuBase Therapeutics' short interest compare to its competitors? 0.51% of NeuBase Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to NeuBase Therapeutics: InMed Pharmaceuticals Inc. (5.92%), Lucy Scientific Discovery Inc. (3.32%), Panbela Therapeutics, Inc. (2.36%), 180 Life Sciences Corp. (5.29%), Biodexa Pharmaceuticals Plc (159.69%), GRI Bio, Inc. (0.46%), PainReform Ltd. (1.17%), Allarity Therapeutics, Inc. (10.38%), Qualigen Therapeutics, Inc. (0.80%), PaxMedica, Inc. (4.65%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short NeuBase Therapeutics stock? Short selling NBSE is an investing strategy that aims to generate trading profit from NeuBase Therapeutics as its price is falling. NBSE shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against NeuBase Therapeutics? A short squeeze for NeuBase Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NBSE, which in turn drives the price of the stock up even further. How often is NeuBase Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NBSE, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: INM Short Interest LSDI Short Interest PBLA Short Interest ATNF Short Interest BDRX Short Interest GRI Short Interest PRFX Short Interest ALLR Short Interest QLGN Short Interest PXMD Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NBSE) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThis 1 Biotech Stock has been shocking the marketsHuge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithUrgent Nvidia WarningAltimetryThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press